TITLE

New Oral Chemotherapeutic Agents for Lung Cancer

AUTHOR(S)
Bengtson, E.M.; Rigas, J.R.
PUB. DATE
December 1999
SOURCE
Drugs;Dec1999 Supplement 3, Vol. 58 Issue 6, p57
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Anticancer treatment has recently shifted to include a broad range of antineoplastic therapies. Old agents are continuously being re-evaluated, and new mechanisms of treatment are rapidly being explored and developed. At the same time, the patient's perceived quality of life, adverse effects of therapy, time demands, and healthcare costs have become paramount in the treatment process. Lung cancer is the most common cause of cancer death in the USA, and because many of the patients are older or debilitated, these issues become all the more important. The oral administration of anticancer therapy offers both quality-of-life and healthcare cost advantages. Oral forms of 3 new cytotoxic agents and 2 novel oral therapies are discussed. Vinorelbine, a vinca alkaloid, has well documented activity in non-small cell lung cancer. Myelosuppression is dose limiting; neurotoxicity is rare. Satraplatin (JM-216), an oral platinum derivative, shows activity in lung cancer with a favourable adverse effect profile, with no neurotoxicity or nephrotoxicity. The oral topoisomerase I inhibitor topotecan may be ideal for obtaining long term low plasma drug concentrations, which appears to maximise efficacy. LGD-1069 is a retinoid X receptor agonist that modulates cell proliferation, and BAY-129566, a matrix metalloproteinase inhibitor, appears to interrupt both the processes of angiogenesis and metastasis. LGD-1069 and BAY-129566 are nontraditional anticancer agents which may be used in conjunction with chemotherapy, other modalities, or in prevention. These 5 agents will be discussed with particular reference to recent developments in the treatment of lung cancer.
ACCESSION #
9593643

 

Related Articles

  • Considerations for Second-Line Therapy of Non-Small Cell Lung Cancer. Stinchcombe, Thomas E.; Socinski, Mark A. // Oncologist;Jan2008 Supplement 1, Vol. 13, p28 

    For patients with advanced non-small cell lung cancer and a good functional status, platinum-based first-line chemotherapy improves quality of life, reduces disease-related symptoms, and improves survival. The addition of bevacizumab to carboplatin and paclitaxel in the first-line setting has...

  • Experimental chemo more cost effective than standard therapy.  // PharmacoEconomics & Outcomes News;12/3/2005, Issue 492, p10 

    The article presents information on a study which examined the cost effectiveness of the experimental chemotherapy combination of cisplatin and gemcitabine for the treatment of patients with non-small-cell lung cancer. The researchers also found that cisplatin/gemcitabine is more effective than...

  • Phase II study of weekly chemotherapy with paclitaxel and gemcitabine as second-line treatment for advanced non-small cell lung cancer after treatment with platinum-based chemotherapy. Mori, Kiyoshi; Kamiyama, Yukari; Kondo, Tetsuro; Kano, Yasuhiko; Kodama, Tetsuro // Cancer Chemotherapy & Pharmacology;Aug2007, Vol. 60 Issue 2, p189 

    We evaluated the tolerability and activity of the combination of weekly paclitaxel (PTX) and gemcitabine (GEM) in second-line treatment of advanced non-small cell lung cancer (NSCLC) after treatment with platinum-based chemotherapy. PTX (100 mg/m2) and GEM (1,000 mg/m2) were administered to...

  • CANCER.  // Nature Reviews Drug Discovery;2004 Hot Drugs, Vol. 3, pS6 

    This article focuses on Gefitinib, a newly approved drug for the treatment of advanced non-small-cell lung cancer. Although cytotoxic chemotherapy has had a major impact on the treatment of some cancers, its efficacy against most solid tumors is limited, and it is associated with significant...

  • Conclusion. Paul A., Bunn Jr.; Thatcher, Nick // Oncologist;Jan2008 Supplement 1, Vol. 13, p37 

    Chemotherapy for non-small cell lung cancer (NSCLC) can prolong survival and improve quality of life, but the majority of advanced stage patients succumb to disease within 2 years, meaning that there is room for improvement. The standard chemotherapy for NSCLC involves one of a number of...

  • Long-term chemotherapy may prolong survival in advanced non-small-cell lung cancer among responders to first-line chemotherapy. Hirashima, Tomonori; Suzuki, Hidekazu; Kobayashi, Masashi; Kondoh, Youko; Tokuoka, Yoshie; Matsuura, Yuka; Tamiya, Motohiro; Morishita, Naoko; Sasada, Shinji; Okamoto, Norio; Akazawa, Kohei; Kawase, Ichiro // Medical Oncology;Sep2012, Vol. 29 Issue 3, p1629 

    Survival in patients with advanced non-small-cell lung cancer (NSCLC) has substantially improved. Long-term chemotherapy with epidermal growth factor tyrosine kinase inhibitors (EGFR-TKIs) and other agents has been associated with long survival. We retrospectively examined the associations...

  • Chemotherpy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life. Spiro, S. G.; Rudd, R. M.; Souhami, R. L.; Brown, J.; Fairlamb, D. J.; Gower, N. H.; Maslove, L.; Milroy, R.; Napp, V.; Parmar, M. K. B.; Peake, M. D.; Stephens, R. J.; Thorpe, H.; Waller, D. A.; West, P. // Thorax;Oct2004, Vol. 59 Issue 10, p828 

    Background: In 1995 a meta-analysis of randomised trials investigating the value of adding chemotherapy to primary treatment for non-small cell lung cancer (NSCLC) suggested a small survival benefit for cisplatin-based chemotherapy in each of the primary treatment settings. However, the meta-...

  • LONG TERM FOLLOW-UP OF NEOADJUVANT-ADJUVANT COMBINATION TREATMENT OF IIIA STAGE NON-SMALL-CELL-LUNG CANCER: RESULTS OF NEOADJUVANT CARBOPLATIN/VINORELBINE AND CARBOPLATIN/PACLITAXEL REGIMENS COMBINED WITH SELECTIVE ADJUVANT CHEMOTHERAPY ACCORDING TO IN-VITRO CHEMORESISTANCE TEST Kolek, Vitezslav; Grygarkova, Ivona; Hajduch, Marian; Klein, Jiri; Cwiertka, Karol; Neoral, Cestmir; Langova, Katerina; Mihal, Vladimir // Biomedical Papers of the Medical Faculty of Palacky University i;2008, Vol. 152 Issue 2, p259 

    Background: A prospective study investigated survival of patients with stage IIIA non-small-cell-lung cancer (NSCLC) treated with a combination of neoadjuvant and adjuvant chemotherapy. Methods: Consecutive chemo-naive patients with potentially operable stage IIIA NSCLC received...

  • Front-line paclitaxel and irinotecan combination chemotherapy in advanced non-small-cell lung cancer: a phase I-II trial. Stathopoulos, G. P.; Dimitroulis, J.; Antoniou, D.; Katis, C.; Tsavdaridis, D.; Armenaki, O.; Marosis, C.; Michalopoulou, P.; Grigoratou, T.; Stathopoulos, J. // British Journal of Cancer;11/14/2005, Vol. 93 Issue 10, p1106 

    Our purpose was to determine the efficacy of irinotecan plus paclitaxel administered on day 1, repeated every 2 weeks, in untreated patients with advanced or metastatic non-small-cell lung cancer (NSCLC). In total, 56 patients with inoperable or metastatic stage III and IV NSCLC with a...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics